BNBX Subsidiary Gains Patent For Enhanced RNA Synthesis

• BNBX, a BNB-focused DAT, has successfully secured patents in the US and Europe for LinearRx’s new RNA Synthesis model.
• The milestone unlocks a new monetization model for the company on top of its BNB strategy.

The subsidiary of BNB Plus Corp. (BNBX), a publicly traded company leveraging a BNB digital asset treasury (DAT) strategy, has successfully secured patents for its RNA synthesis breakthrough. LineaRx Inc. has now reinforced its intellectual property (IP) portfolio in both the US and Europe.

After its US grant in 2024, the European Patent Office (EPO) has recently approved LineaRx’s “Compositions and Methods for RNA Synthesis.” The agency filed it under European Patent Application No.: 21882234.4 (EP4232569A1).

LineaRx’s Revolutionary RNA Synthesis Model

According to LineaRx’s press release on Wednesday, the patent covers its chemically modified RNA polymerase (RNAP) enzyme, branded Linea RNAP. The product serves as a vital component of its IVT (in vitro transcription) platform, enabling biopharmaceutical manufacturers to produce enhanced mRNA via a streamlined workflow with reduced double-stranded RNA (dsRNA) contamination.

ADVERTISEMENTIn layman’s terms, the process results in more efficient, higher-quality outputs than conventional mRNA bioengineering methods. It particularly reduces the risk of impurities and unintended immune responses in patients.

Why This Matters for BNBX

The patent protects LineaRx’s IP, enabling it to potentially monetize its revolutionary mRNA synthesis model. Clary Shorrock, CEO of BNBX, considers the achievement a major milestone in their company profile.

“Securing patent protection in Europe is a significant milestone in building our global intellectual property portfolio around Linea IVT,” said Shorrock. “Together with our US patent, this European grant strengthens LineaRx’s position to help mRNA manufacturers produce higher-quality mRNA more efficiently and supports potential monetization of the Company’s intellectual property in the rapidly growing European biotherapeutics market.”

ADVERTISEMENT## BNBX’s BNB-Focused DAT Strategy

BNB Plus Corp. has integrated a DAT strategy focused on BNB in October 2025. It consequently rebranded from Applied DNA to its current name in the following month to reflect its new identity.

As of March 18, 2026, BNBX maintains 17,537.92 BNB in its treasury. At BNB’s prevailing price of $652 per token, the haul amounts to $11.43 million.

BNBX possesses a standard market cap of $4.27 million, or $7.9 million if including prefunded warrants.

BNB’s slump, along with the broader crypto market, led to BNBX’s standard mNAV (Market-to-Net-Asset-Value) ratio falling to a dangerously low 0.35. Including its prefunded warrants keeps the ratio at 0.65.

Nonetheless, BNBX grounded its BNB accumulation for a long hold, betting on the asset’s utility rather than mere short-term price action, market sentiment, or speculations. Additionally, the company’s dual-engine model, combining a DAT playbook with high-value biotech IP, provides a unique value proposition that’s resistant to crypto market volatility.

ADVERTISEMENT